RxDoctor Payments Data

Irving Perez Guzman, MD

Cardiovascular Disease · Sebring, FLNPI 1437599255

Payments from drug & device makers

$5,109in general payments, 2019–2025

Across 108 payments — averaging $47.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotronik Inc.$2K
  • Pfizer$373
  • Medtronic$338
  • Boston Scientific$321
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$301
  • AstraZeneca$264
  • plus $1K from 14 others

What the payments were for

  • Travel & lodging$1,26225%
  • Food & beverage$3,79374%
  • Education$541%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,109 in reported general payments places this provider in the 55th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$185,420
Medicare patients
416
Services billed
1,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban104$119,832
JardianceEmpagliflozin66$78,936
EntrestoSacubitril/Valsartan28$40,633
Repatha SureclickEvolocumab21$31,220
XareltoRivaroxaban26$26,671
CorlanorIvabradine Hcl12$10,299
Atorvastatin Calcium230$2,436
Metoprolol Succinate203$2,158
Ranolazine ErRanolazine18$1,789
Carvedilol172$1,230
ClopidogrelClopidogrel Bisulfate74$885
Hydralazine Hcl56$846
Losartan Potassium68$727
Rosuvastatin Calcium66$651
Bumetanide20$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$373$119,832104 claims
NovartisEntresto$66$40,63328 claims
Johnson & JohnsonXarelto$153$26,67126 claims
AmgenCorlanor$38$10,29912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Sebring

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →